Malaysia-based IHH Healthcare has led a $20-million Series A funding round for Singapore-based Lucence, the inventor of blood-based tests for cancer screening and treatment selection, the companies announced Wednesday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
